Akebia Therapeutics Inc (NASDAQ:AKBA) price on current trading day, fall -2.60% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.56.
A look at the stock’s price movement, the level at last check in today’s session was $3.65, moving within a range at $3.54 and $3.63. The beta value (5-Year monthly) was 0.843. Turning to its 52-week performance, $4.08 and $0.80 were the 52-week high and 52-week low respectively. Overall, AKBA moved 45.10% over the past month.
Akebia Therapeutics Inc’s market cap currently stands at around $933.67 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-07.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend AKBA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AKBA’s current price about 9.11% and 36.55% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.45, while 7-day volatility ratio is 5.57% and 4.17% in the 30-day chart. Further, Akebia Therapeutics Inc (AKBA) has a beta value of 0.86, and an average true range (ATR) of 0.22. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $6 and high of $7. Looking at the price targets, the low is -68.54% off recent price level in today’s trading while to achieve the yearly target high, it has to move -96.63%. Nonetheless, investors will most likely welcome a -82.58% jump to $6.5 which is the analysts’ median price.
If we refocus on Akebia Therapeutics Inc (NASDAQ:AKBA), historical trading data shows that trading volumes averaged 7.91 over the past 10 days and 5.64 million over the past 3 months. The company’s latest data on shares outstanding shows there are 261.64 million shares.
The 4.10% of Akebia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 36.53% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 20.05 million on 2025-05-30, giving us a short ratio of 4.2. The data shows that as of 2025-05-30 short interest in Akebia Therapeutics Inc (AKBA) stood at 771.99996 of shares outstanding, with shares short rising to 17.77 million registered in 2025-04-30. Current price change has pushed the stock 87.11% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AKBA stock continues to rise going into the next quarter.
